Fig 1: Levels of inflammasome protein in the CSF of patients with CABM. (A, C–F) Levels of CSF NLRP1, NLRC4, AIM2, ASC, and caspase-1 were not different among the three groups. (B) Concentrations of CSF NLRP3 in the CABM group were significantly higher than those in the VM (p < 0.001) and control (p < 0.001) groups. ****p < 0.001.
Fig 2: Melanoma specimens reduce PRGs positive cells in epidermal clinically.A Overall survival analysis based on K-M was calculated to identify the potential PRGs clinically. B PPI via MCODE and CytoNCA algorithm was established, in which PRGs were screened out as central protein functioning in melanoma deficiency. C GZMA, GSDMB, CHMP4A, NLRP1, and IL18 protein expression of melanoma and control patients detected by ELISA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 5, compared with the normal group. D Representative IHC stanning of GZMA+, GSMDB+, CHMP4A+, NLRP1+, and IL18+ in melanoma specimens from the clinic. Scale bar = 100 µm, n = 5 samples per group. E The quantification of PRGs protein in epidermal areas, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, compared with the control group.
Fig 3: PRGs were primarily expressed in immune cells.A Feature plots depicting the expression of key pyroptosis, violin plots were also displayed to determine the cell type. B Representative IHC stanning of GZMA+, GSMDB+, CHMP4A+, NLRP1+, and IL18+ in melanoma specimens, especially in lymphocyte areas. Scale bar = 100 µm, n = 4 samples per group. C The quantification of PRGs protein in dermal areas, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, compared with the control group.
Supplier Page from CUSABIO Technology LLC for Human NACHT, LRR and PYD domains-containing protein 1(NLRP1) ELISA Kit